For research use only, not for therapeutic use.
RAF265（Cat No.:I005517）is a potent, multikinase inhibitor targeting RAF family kinases, particularly BRAF, including both wild-type and mutant forms, as well as VEGFR2. By inhibiting BRAF and VEGFR2, RAF265 blocks the MAPK/ERK signaling pathway, leading to reduced tumor cell proliferation and angiogenesis. It has demonstrated activity in preclinical and clinical studies against tumors harboring BRAF mutations, such as melanoma, and other cancers dependent on RAF and VEGFR-driven growth. RAF265 is a valuable tool in oncology research for investigating the inhibition of oncogenic signaling and the suppression of tumor progression and angiogenesis.
| Catalog Number | I005517 |
| CAS Number | 927880-90-8 |
| Synonyms | RAF-265 |
| Molecular Formula | C₂₄H₁₆F₆N₆O |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | DMSO: ≥ 26 mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 3-60 nM (B-Raf); 30 nM(EC50 for VEGFR2) |
| IUPAC Name | 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine |
| InChI | InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34) |
| InChIKey | YABJJWZLRMPFSI-UHFFFAOYSA-N |
| SMILES | CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F |
| Reference | <p> |
